UNIVERSITY OF VIRGINIA MEDICAL CENTE
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $116.6M
- Transactions
- 10,804
- Companies
- 40
- Average per transaction
- $10,796
Who reported the payments
| Seagen Inc. | $6,839,715 |
| Merck | $6,471,105 |
| AstraZeneca | $6,289,156 |
| Janssen Research & Development, LLC | $5,600,900 |
| Edwards Lifesciences | $5,430,931 |
| Tandem Diabetes Care, Inc. | $5,318,309 |
| Regeneron | $4,600,911 |
| Pfizer | $3,998,996 |
| Novo Nordisk AS | $3,472,757 |
| Abbott | $3,366,499 |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,233,780 |
| Medtronic | $2,832,495 |
| E.r. Squibb & Sons, L.L.C. | $2,791,771 |
| Beigene, Ltd. | $2,690,232 |
| Exelixis Inc. | $2,507,483 |
| Gilead | $2,504,308 |
| Amgen | $2,365,845 |
| AbbVie | $2,050,793 |
| Genentech, Inc. | $1,969,431 |
| Eli Lilly | $1,904,643 |
| Astrazeneca UK Limited | $1,812,194 |
| Boston Scientific | $1,620,785 |
| Biomarin Pharmaceutical Inc. | $1,333,495 |
| Vertex | $1,239,204 |
| Bristol Myers Squibb | $1,195,884 |
| Novartis | $1,170,126 |
| Siemens Medical Solutions USA, Inc. | $1,161,562 |
| Insulet Corporation | $1,090,896 |
| Globus Medical | $1,069,245 |
| Pharmaessentia USA Corporation | $1,002,155 |
| CSL Behring | $915,400 |
| Daiichi Sankyo Inc. | $843,019 |
| Insightec,ltd | $694,558 |
| Dexcom, Inc. | $623,403 |
| Orthofix Medical, Inc. | $615,969 |
| Sumitomo Pharma America, Inc. | $608,354 |
| Incyte Corporation | $561,212 |
| United Therapeutics Corporation | $533,243 |
| Biogen | $494,246 |
| Stemline Therapeutics Inc. | $488,821 |